However, a pivotal phase III trial of the Immuno C1INH concentrate (Baxter Healthcare) for acute HAE attacks failed to show any improvement in C1INH-treated compared to placebo-treated subjects. This evidence concerns the gene SERPING1 and hereditary angioedema.